Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00779480 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)
A Phase 1 study, sponsored by Kyowa Kirin Co..
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00779480 is a Phase 1 study that was terminated before completion, run by Kyowa Kirin Co.. The registered enrollment target is 14 participants.
The verdict
NCT00779480, a Phase 1 study, was terminated before completion, sponsored by Kyowa Kirin Co..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
To determine the maximum tolerated dose of KW-2449 in people with acute myelogenous leukemia who are not candidates for approved therapy. As well, the study will determine the response rate to KW-2449.
Interventions
- DRUG KW-2449
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2009-01 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00779480
The ClinicalTrials.gov registry entry for NCT00779480 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin Co., which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KW-2449 is the first listed.
NCT00779480 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00779480 about?
NCT00779480 is a clinical study titled "Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)". To determine the maximum tolerated dose of KW-2449 in people with acute myelogenous leukemia who are not candidates for approved therapy. As well, the study will determine the response rate to KW-2449.
What is the current status of trial NCT00779480?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2009-01. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00779480?
The interventions under investigation include: KW-2449 (DRUG).
Who is sponsoring clinical trial NCT00779480?
This trial is sponsored by Kyowa Kirin Co., which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.